Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
Bill is filed in its originating chamber and assigned a number.
Sponsor
Mike Lee (R-UT)
Filed in the Senate.
Next: In Committee
Members of the committee(s) the bill was referred to
Reduces regulatory requirements for biosimilar drug approval and marketing in the United States.
The problem
Biosimilar drugs face lengthy approval processes and strict labeling rules, making them expensive and slow to reach patients compared to other countries.
The proposal
Streamlines FDA approval pathways, reduces post-market monitoring requirements, and simplifies labeling standards for biosimilar medications to speed market entry.
The impact
Patients, drug manufacturers, and the healthcare system. Patients may access cheaper drugs faster. Manufacturers face lower compliance costs. Drug safety oversight could be affected.
Faster biosimilar approval reduces time to market, increasing competition and potentially lowering prices for patients and insurers. This could save billions in healthcare spending.
Streamlined approval means patients get life-saving medications sooner. Countries with faster biosimilar pathways have seen quicker treatment options available.
Lower regulatory costs help manufacturers, especially smaller companies, bring biosimilars to market. This encourages innovation and competition in the drug industry.
U.S. standards would better match Europe and other countries, reducing duplicate testing and creating efficiency in global drug development.
Reducing post-market monitoring could miss rare side effects that appear after drugs are widely used. Patients might experience unexpected health problems without proper tracking.
Fewer requirements for labeling and tracking could make it harder for doctors and patients to understand medication differences and report problems.
Biosimilars are complex; reducing safety requirements may not catch problems that take years to develop. Patients could face unknown risks.
Faster approval processes might approve medications before full safety data exists, prioritizing speed over thorough testing and evidence.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.